Last reviewed · How we verify
NCT00652184
Phase 2/3 Multi-Center, Double-Blind, Controlled Trial Comparing Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir, and Combination Topical ARYS-01 Cream /Oral Valaciclovir for Treatment of Herpes Zoster in Immunocompetent Patients 18 Years of Age or Older
Phase 2 trial testing ARYS-01 (sorivudine) cream 3% or placebo cream in Herpes Zoster in 300 participants. Status unknown.
1 June 2009
Quick facts
| Lead sponsor | aRigen Pharmaceuticals, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 300 |
| Start date | 1 March 2008 |
| Primary completion | 1 June 2009 |
| Estimated completion | 1 September 2009 |
| Sites | 10 locations across United States |
Drugs / interventions tested
- ARYS-01 (sorivudine) cream 3% or placebo cream — full drug profile →
- placebo
- valaciclovir (valaciclovir) — full drug profile →
Conditions studied
- Herpes Zoster — all drugs for Herpes Zoster →
- Postherpetic Neuralgia — all drugs for Postherpetic Neuralgia →
Sponsor
aRigen Pharmaceuticals, Inc. — full company profile →
Who can join
18 and older, any sex, with Herpes Zoster or Postherpetic Neuralgia. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
The effect of ARYS-01 (sorivudine) cream (with or without Valaciclovir) on the reduction of the crusting stage of VZV rash present at Day 8.
Time frame: Day 8
Sponsor's own description
A multi-center, randomized, 4-arm, placebo-controlled, double-blind efficacy study of ARYS-01 (sorivudine) cream 3%.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Viremia in acute herpes zoster.
Satyaprakash AK, Tremaine AM, Stelter AA, Creed R, et al · · 2009 · cited 28× · PMID 19469706 · DOI 10.1086/599381
Verify or expand the search:
- PubMed search for NCT00652184
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Herpes Zoster
Currently open trials in the same condition.
- NCT07400003 — Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine · Phase 1, PHASE2 · recruiting
- NCT07307170 — The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster · NA · recruiting
- NCT07293065 — A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell) · Phase 3 · active not recruiting
- NCT07361796 — The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes · NA · recruiting
- NCT07378046 — The Analgesic Efficacy and Safety of Baclofen in Patients With Herpes Zoster · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00652184 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by aRigen Pharmaceuticals, Inc.
- Last refreshed: 3 October 2008
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00652184.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing